KMT2A and cancer: MLLT3 has primarily been studied in cancer, where its truncation and fusion with MLL1 leads to aberrant H3K79 methylation, dysregulating the JNK (Sun et al., 2017) and WNT (Zhang et al., 2019) pathways.